[1]
|
常路晗, 王银月, 崔伊曼, 等. 冬凌草甲素脂质体的制备及体内药动学研究[J]. 山西医科大学学报, 2023, 54(1): 119-124. https://doi.org/10.13753/j.issn.1007-6611.2023.01.018
|
[2]
|
郑海娜. 冬凌草甲素的药代动力学和组织分布研究[D]: [硕士学位论文]. 开封: 河南大学, 2011.
|
[3]
|
耿挺. 科学家揭示冬凌草药效成分生物合成机制[N]. 上海科技报, 2022-12-21(006). https://doi.org/10.28704/n.cnki.nshkj.2022.001440
|
[4]
|
付玉, 王淑静, 张家宁. 冬凌草甲素的药理活性及作用机制研究[J]. 食品与药品, 2022, 24(2): 202-207.
|
[5]
|
郭杰, 郝楠. 冬凌草的化学成分及药理研究进展[J]. 兰州职业技术学院学报, 2022, 38(2): 65-66, 84.
|
[6]
|
夏经纬, 沈波. 肠道微生物在肺癌发生发展及治疗中的研究进展[J]. 南京医科大学学报(自然科学版), 2024, 44(1): 130-137.
|
[7]
|
王竞, 曾黎丽, 孔令平, 等. Klotho在肺癌中的研究进展[J]. 中国肺癌杂志, 2023, 26(6): 473-478.
|
[8]
|
刘超, 裴圣林. 外泌体调控肺癌肿瘤微环境机制和临床应用的研究进展[J]. 广西医科大学学报, 2024, 41(3): 464-470. https://doi.org/10.16190/j.cnki.45-1211/r.2024.03.020
|
[9]
|
靖林林, 龚先玲, 孙学刚. 自噬的中医属性及其在人体衰老和肿瘤发病中的意义[J]. 中医杂志, 2014, 55(22): 1891-1893. https://doi.org/10.13288/j.11-2166/r.2014.22.001
|
[10]
|
罗帅, 陈勇. 冬凌草甲素联合免疫因子TRAF4对非小细胞肺癌细胞自噬和凋亡的影响及机制研究[J]. 天津中医药, 2023, 40(11): 1484-1489.
|
[11]
|
李思锐. 冬凌草素调控非小细胞肺癌细胞凋亡提高其放疗敏感性的作用研究[D]: [硕士学位论文]. 长春: 吉林大学, 2017.
|
[12]
|
彭蕾, 薛仁宇, 顾振纶, 等. 冬凌草甲素对人肺腺癌细胞株SPC-A-1增殖和凋亡的影响[J]. 中国药理学通报, 2010, 26(4): 558-559.
|
[13]
|
Liu, J., Huang, R., Lin, D., Peng, J., Wu, X., Pan, X., et al. (2004) Anti-proliferative Effects of Oridonin on SPC-A-1 Cells and Its Mechanism of Action. Journal of International Medical Research, 32, 617-625. https://doi.org/10.1177/147323000403200606
|
[14]
|
Liu, Y., Liu, J., Chai, K., Tashiro, S., Onodera, S. and Ikejima, T. (2013) Inhibition of C-Met Promoted Apoptosis, Autophagy and Loss of the Mitochondrial Transmembrane Potential in Oridonin-Induced A549 Lung Cancer Cells. Journal of Pharmacy and Pharmacology, 65, 1622-1642. https://doi.org/10.1111/jphp.12140
|
[15]
|
Liu, Y., Shi, Q., Qi, M., Tashiro, S., Onodera, S. and Ikejima, T. (2012) Interruption of Hepatocyte Growth Factor Signaling Augmented Oridonin-Induced Death in Human Non-Small Cell Lung Cancer A549 Cells via C-Met-Nuclear Factor-κB-Cyclooxygenase-2 and C-Met-Bcl-2-Caspase-3 Pathways. Biological and Pharmaceutical Bulletin, 35, 1150-1158. https://doi.org/10.1248/bpb.b12-00197
|
[16]
|
刘莹. 肝细胞生长因子受体抑制剂SU11274及冬凌草甲素诱导人非小细胞肺癌A549细胞死亡的机制研究[D]: [博士学位论文]. 沈阳: 沈阳药科大学, 2012.
|
[17]
|
金娟. 冬凌草甲素诱导肺癌A549细胞凋亡及机制研究[D]: [硕士学位论文]. 衡阳: 南华大学, 2009.
|
[18]
|
彭蕾. 冬凌草甲素对人肺腺癌SPC-A-1细胞的抑制作用及其机制研究[D]: [硕士学位论文]. 苏州: 苏州大学, 2010.
|
[19]
|
张守伟, 刘加军. 复方冬凌草甲素对肺癌SPCA-1细胞的端粒酶活性的影响[J]. 临床肺科杂志, 2003, 8(3): 204-206.
|
[20]
|
Wang, Y., Lv, Y., Lu, L. and Cai, L. (2014) Oridonin Inhibits mTOR Signaling and the Growth of Lung Cancer Tumors. Anti-Cancer Drugs, 25, 1192-1200. https://doi.org/10.1097/cad.0000000000000154
|
[21]
|
杨桦鸿. 冬凌草甲素对非小细胞肺癌细胞增殖和顺铂耐药的作用及机制研究[D]: [博士学位论文]. 长春: 吉林大学, 2020. https://doi.org/10.27162/d.cnki.gjlin.2020.000279
|
[22]
|
Nkyimbeng-Takwi, E. and Chapoval, S.P. (2011) Biology and Function of Neuroimmune Semaphorins 4A and 4D. Immunologic Research, 50, 10-21. https://doi.org/10.1007/s12026-010-8201-y
|
[23]
|
何国浓, 贺志良, 王邦才, 等. 冬凌草甲素靶向Sema4D抑制人非小细胞肺癌A549细胞增殖的机制研究[J]. 中华中医药杂志, 2021, 36(7): 3842-3846.
|
[24]
|
何国浓, 王邦才, 沈洁如, 等. 冬凌草甲素基于下调Sema4D抑制A549裸鼠移植瘤增殖的机制研究[J]. 中华中医药学刊, 2021, 39(10): 231-235, 274-275. https://doi.org/10.13193/j.issn.1673-7717.2021.10.055
|
[25]
|
Zheng, M., Zhu, Z., Zhao, Y., Yao, D., Wu, M. and Sun, G. (2016) Oridonin Promotes G2/M Arrest in A549 Cells by Facilitating ATM Activation. Molecular Medicine Reports, 15, 375-379. https://doi.org/10.3892/mmr.2016.6008
|
[26]
|
常乐, 李泽庚, 王婕琼. 从“诸气膹郁, 皆属于肺”探讨郁证从肺论治[J]. 中国民族民间医药, 2017, 26(2): 1-2, 7.
|
[27]
|
肖香玲, 何中维, 黄秋月, 等. 冬凌草甲素下调EGFR/ERK/MMP-12和CIP2A/Akt信号通路抑制gefitinib耐受的非小细胞肺癌的转移[J]. 湖北医药学院学报, 2016, 35(6): 536-542, 629. https://doi.org/10.13819/j.issn.1006-9674.2016.06.003
|
[28]
|
王健, 周雯, 宋秀宇, 等. 冬凌草甲素对人肺癌A549和PC-9细胞侵袭的抑制作用和机制研究[J]. 天津医药, 2015, 43(9): 965-969.
|
[29]
|
柳悄然, 张在云, 于晓明, 等. 冬凌草甲素对人肺癌NCI-H460细胞侵袭和迁移的影响[J]. 中国病理生理杂志, 2014, 30(8): 1497-1500, 1518.
|
[30]
|
Abdullah, N.A., Md Hashim, N.F., Ammar, A. and Muhamad Zakuan, N. (2021) An Insight into the Anti-Angiogenic and Anti-Metastatic Effects of Oridonin: Current Knowledge and Future Potential. Molecules, 26, Article 775. https://doi.org/10.3390/molecules26040775
|
[31]
|
Xu, L., Bi, Y., Xu, Y., Zhang, Z., Xu, W., Zhang, S., et al. (2020) Oridonin Inhibits the Migration and Epithelial‐to‐Mesenchymal Transition of Small Cell Lung Cancer Cells by Suppressing FAK‐ERK1/2 Signalling Pathway. Journal of Cellular and Molecular Medicine, 24, 4480-4493. https://doi.org/10.1111/jcmm.15106
|
[32]
|
Park, H., Jeong, Y.J., Han, N., Kim, J.S. and Lee, H. (2018) Oridonin Enhances Radiation-Induced Cell Death by Promoting DNA Damage in Non-Small Cell Lung Cancer Cells. International Journal of Molecular Sciences, 19, Article 2378. https://doi.org/10.3390/ijms19082378
|
[33]
|
Yang, H., Gao, Y., Fan, X., Liu, X., Peng, L. and Ci, X. (2019) Oridonin Sensitizes Cisplatin-Induced Apoptosis via AMPK/Akt/mTOR-Dependent Autophagosome Accumulation in A549 Cells. Frontiers in Oncology, 9, Article 769. https://doi.org/10.3389/fonc.2019.00769
|
[34]
|
付玉. 基于能量代谢体外研究冬凌草甲素抗肿瘤活性[D]: [硕士学位论文]. 哈尔滨: 哈尔滨商业大学, 2022. https://doi.org/10.27787/d.cnki.ghrbs.2022.000310
|
[35]
|
Li, S., Shi, D., Zhang, L., Yang, F. and Cheng, G. (2018) Oridonin Enhances the Radiosensitivity of Lung Cancer Cells by Upregulating Bax and Downregulating Bcl-2. Experimental and Therapeutic Medicine, 16, 4859-4864. https://doi.org/10.3892/etm.2018.6803
|
[36]
|
Fan, X., Wang, T., Ji, Z., Li, Q., Shen, H. and Wang, J. (2021) Synergistic Combination Therapy of Lung Cancer Using Lipid-Layered Cisplatin and Oridonin Co-Encapsulated Nanoparticles. Biomedicine & Pharmacotherapy, 141, Article ID: 111830. https://doi.org/10.1016/j.biopha.2021.111830
|